View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 1, 2021

Vela Diagnostics expands Covid-19 portfolio offering with new assays

Vela Diagnostics has announced the addition of two assays, ViroKey SQ FLEX SARS-CoV-2 Genotyping Assay and ViroKey SARS-CoV-2 ID RT-PCR Test, to its Covid-19 portfolio offering.

Vela Diagnostics has announced the addition of two assays, ViroKey SQ FLEX SARS-CoV-2 Genotyping Assay and ViroKey SARS-CoV-2 ID RT-PCR Test, to its Covid-19 portfolio offering.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Using next-generation sequencing (NGS) technology, the genotyping assay sequences the whole SARS-CoV-2 genome, and accompanying Sentosa SQ Reporter software identifies mutations and categories them by lineage.

This process helps in the research and interpretation of the molecular epidemiology of Covid-19.

To increase the effectiveness / sensitivity of molecular diagnostics, serological assays, vaccine design, and anti-viral therapy, whole-genome sequencing is necessary. It also helps in studying routes of transmission and outbreak clusters, the World Health Organization (WHO) said.

Vela Diagnostics managing director Andreas Goertz said: “We offer a highly automated workflow, which requires less than two hours of hands-on time from sample to report generation.

“With this ease-of-use, laboratories can very quickly adopt an NGS solution that would become an important tool in this pandemic situation.”

The ViroKey SARS-CoV-2 ID RT-PCR Test (RUO) can potentially detect variants such as B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) lineages in the positive samples rapidly.

Vela Diagnostics Business Development director Scott Cassidy said: “With emerging variants like the recent B.1.526 from New York that may weaken vaccine effectiveness, the need for mutation identification becomes clear.

“We are now able to offer options for quick detection of known variants of concerns, and all future variants for better pandemic management.”

The company noted that the variant identification test can be used, along with the ViroKey SARS-CoV-2 RT-PCR Test v2.0, which has obtained the US Food and Drug Administration (FDA) emergency use authorisation (EUA), CE-IVD, and TGA approval, and HSA provisional authorisation.

Using the automated Sentosa platform, Vela’s test solutions offer a distinctive ability to leverage a single system for NGS and PCR testing in infectious disease and oncology.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network